CoChat

First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial

Tung, Roderick, Xue, Yumei, Chen, Minglong, Jiang, Chenyang, Shatz, Dalise Y., Besser, Stephanie A., Hu, Hongde, Chung, Fa-Po, Nakahara, Shiro, Kim, Young-Hoon, Satomi, Kazuhiro, Shen, Lishui, Liang, Er’peng, Liao, Hongtao, Gu, Kai, Jiang, Ruhong, Jiang, Jian, Hori, Yuichi, Choi, Jong-Il, Ueda, Akiko, Komatsu, Yuki, Kazawa, Shuichiro, Soejima, Kyoko, Chen, Shih-Ann, Nogami, Akihiko, Yao, Yan, on behalf of PAUSE-SCD Investigators · 2022 · Circulation
Cited by 170

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Background: Catheter ablation as first-line therapy for ventricular tachycardia (VT) at the time of implantable cardioverter defibrillator (ICD) implantation has not been adopted into clinical guidelines. Also, there is an unmet clinical need to prospectively examine the role of VT ablation in patients with nonischemic cardiomyopathy, an increasingly prevalent population that is referred for advanced therapies globally. Methods: We conducted an international, multicenter, randomized controlled trial enrolling 180 patients with cardiomyopathy and monomorphic VT with an indication for ICD implantation to assess the role of early, first-line ablation therapy. A total of 121 patients were randomly assigned (1:1) to ablation plus an ICD versus conventional medical therapy plus an ICD. Patients who refused ICD (n=47) were followed in a prospective registry after stand-alone ablation treatment. The primary outcome was a composite end point of VT recurrence, cardiovascular hospitalization, or death. Results: Randomly assigned patients had a mean age of 55 years (interquartile range, 46–64) and left ventricular ejection fraction of 40% (interquartile range, 30%–49%); 81% were male. The underlying heart disease was ischemic cardiomyopathy in 35%, nonischemic cardiomyopathy in 30%, and arrhythmogenic cardiomyopathy in 35%. Ablation was performed a median of 2 days before ICD implantation (interquartile range, 5 days before to 14 days after). At 31 months, the primary outcome occurred in 49.3% of the ablation group and 65.5% in the control group (hazard ratio, 0.58 [95% CI, 0.35–0.96]; P =0.04). The observed difference was driven by a reduction in VT recurrence in the ablation arm (hazard ratio, 0.51 [95%CI, 0.29–0.90]; P =0.02). A statistically significant reduction in both ICD shocks (10.0% versus 24.6%; P =0.03) and antitachycardia pacing (16.2% versus 32.8%; P =0.04) was observed in patients who underwent ablation compared with control. No differences in cardiovascular hospitalization (32.0% versus. 33.7%; hazard ratio, 0.82 [95% CI, 0.43–1.56]; P =0.55) or mortality (8.9% versus 8.8%; hazard ratio, 1.40 [95% CI, 0.38–5.22]; P =0.62]) were observed. Ablation-related complications occurred in 8.3% of patients. Conclusions: Among patients with cardiomyopathy of varied causes, early catheter ablation performed at the time of ICD implantation significantly reduced the composite primary outcome of VT recurrence, cardiovascular hospitalization, or death. These findings were driven by a reduction in ICD therapies. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02848781.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1161/circulationaha.122.060039

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Metadata

Authors
Tung, R., Xue, Y., Chen, M., Jiang, C., Shatz, D. Y., Besser, S. A., Hu, H., Chung, F.-P., Nakahara, S., Kim, Y.-H., Satomi, K., Shen, L., Liang, E., Liao, H., Gu, K., Jiang, R., Jiang, J., Hori, Y., Choi, J.-I., Ueda, A., Komatsu, Y., Kazawa, S., Soejima, K., Chen, S.-A., Nogami, A., Yao, Y., & on behalf of PAUSE-SCD Investigators
Venue
Circulation
Published
2022-06-21
Volume
145
Issue
25
Pages
1839-1849
ISSN
  • 0009-7322 (ISSN-L)
  • 1524-4539
OpenAlex
W4225378087
Cited by
170
References
4
FWCI
21.81
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial. https://app.cochat.ai/papers/10.1161/circulationaha.122.060039
The paper
Tung, R., Xue, Y., Chen, M., Jiang, C., Shatz, D. Y., Besser, S. A., Hu, H., Chung, F.-P., Nakahara, S., Kim, Y.-H., Satomi, K., Shen, L., Liang, E., Liao, H., Gu, K., Jiang, R., Jiang, J., Hori, Y., Choi, J.-I., . . . on behalf of PAUSE-SCD Investigators. (2022). First-Line Catheter Ablation of Monomorphic Ventricular Tachycardia in Cardiomyopathy Concurrent With Defibrillator Implantation: The PAUSE-SCD Randomized Trial. Circulation. https://doi.org/10.1161/circulationaha.122.060039

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.